BioScrip, Inc. (BIOS)
(Delayed Data from NSDQ)
$1.98 USD
+0.05 (2.59%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.98 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.98 USD
+0.05 (2.59%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.98 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Option Care (BIOS) Down 12% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Option Care (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Option Care Health (BIOS) Surges: Stock Moves 7.3% Higher
by Zacks Equity Research
Option Care Health (BIOS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Option Care is the Preferred Provider of Haemophilia Treatment
by Zacks Equity Research
Option Care Health (BIOS) can currently access all hemophilia factor treatments.
Option Care Health (BIOS) Q3 Earnings Meet, Revenues Top
by Zacks Equity Research
Albeit Option Care Health (BIOS) is yet to reap material benefits from its merger-related synergies, the reporting of a positive gross margin in third-quarter results is encouraging for investors.
Option Care (BIOS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Option Care (BIOS) delivered earnings and revenue surprises of 0.00% and 17.94%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Option Care (BIOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Option Care (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Learn How to Find Top-Ranked 'Cheap' Stocks Under $10 with this Screener
by Benjamin Rains
Searching for 'cheap' stocks that look poised to climb can be an attractive investment strategy. But investors have to know where and how to find strong stocks trading under $10 a share. So check out this Zacks Stock Screener...
Here's Why Momentum Investors Will Love BioScrip (BIOS)
by Zacks Equity Research
Does BioScrip (BIOS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Moving Average Crossover Alert: Option Care Health
by Zacks Equity Research
Option Care Health is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Top Ranked Momentum Stocks to Buy for September 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 12th
BioScrip Closes Option Care Merger, Incurs Wider Q2 Loss
by Zacks Equity Research
With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.
BioScrip (BIOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioScrip (BIOS) delivered earnings and revenue surprises of -30.00% and 3.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
BioScrip, Inc. (BIOS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in BioScrip, Inc. (BIOS).
BioScrip, Inc.'s Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in BioScrip.
BioScrip (BIOS) Up 5.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioScrip's Option Care Merger on Track, Q1 Loss Narrows
by Zacks Equity Research
BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.
BioScrip (BIOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
BioScrip (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioScrip (BIOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioScrip (BIOS) delivered earnings and revenue surprises of 16.67% and 0.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Moving Average Crossover Alert: BioScrip
by Zacks Equity Research
BioScrip, Inc. (BIOS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Why Is BioScrip (BIOS) Down 50.4% Since Last Earnings Report?
by Zacks Equity Research
BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for April 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for April 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for April 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
BioScrip (BIOS) Reports Loss in Q4, Both Margins Contract
by Zacks Equity Research
The combined expertise of BioScrip (BIOS) and OptionCare is expected to drive significant growth for the former.
Do Options Traders Know Something About BioScrip (BIOS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to BioScrip (BIOS) stock based on the movements in the options market lately.